Notably, OPN-neutralizing antibodies have shown promising anti-tumor effects in preclinical models of breast cancer, colorectal cancer, and melanoma, further validating the therapeutic potential of OPN modulation in cancer treatment [139]. Here, SPP1 is linked to neoplasm.